Abbott is tapping the spirit of new beginnings for the New Year by unveiling a “gamechanger" feature within the company’s ...

A phase 3 study of Zenas BioPharma's autoimmune disease candidate has hit its primary endpoint. But, with the result falling ...

MetaVia has shared an update on its attempt to crash the obesity party, reporting average weight loss of 9.1% in people who ...

Sanofi has returned to U.S. artificial intelligence research biotech Earendil Labs for another significant autoimmune and ...

Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026. | Aktis ...

Biobeat Technologies has raised $50 million in a series B round to help boost the commercialization of its blood pressure ...

The June agreement established a fixed revenue-sharing model, with TME Pharma receiving a “larger share of future licensing ...

In 2025, biopharma layoffs showed no signs of slowing, instead rising 16% year over year. | In 2025, biopharma layoffs showed ...

Right on the heels of its IPO, Insilico Medicine is starting the year with an oncology discovery and development pact with French pharma Servier.  | Right on the heels of its IPO, Insilico Medicine is ...

Elon Musk’s Neuralink is shifting into high gear for 2026 as the company’s co-founder touts changes to the brain-computer ...

The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...

Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...